Last reviewed · How we verify
thioacetazone
thioacetazone is a drug. It is currently in unknown development for Pulmonary tuberculosis.
Thioacetazone, also known as amithiozone, is a small molecule oral antibiotic used in the treatment of tuberculosis. It has been studied for its potential use in treating Mycobacterium Avium-intracellulare Infection and multidrug-resistant tuberculosis.
At a glance
| Generic name | thioacetazone |
|---|---|
| Therapeutic area | Infectious Disease |
| Phase | unknown |
Approved indications
- Pulmonary tuberculosis
Common side effects
Key clinical trials
- The Individualized M(X) Drug-resistant TB Treatment Strategy Study A Strategy to Improve Treatment Outcomes in Patients With Drug-resistant TB (Phase 4)
- NCT00004689 (Phase 2)
- Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis (N/A)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- thioacetazone CI brief — competitive landscape report
- thioacetazone updates RSS · CI watch RSS
- portfolio CI
Frequently asked questions about thioacetazone
What is thioacetazone?
What is thioacetazone used for?
What development phase is thioacetazone in?
Related
- Manufacturer: — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for Pulmonary tuberculosis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing